Eledon Pharmaceuticals (2TK) AI Stock Analysis

Eledon Pharmaceuticals

(Frankfurt:2TK)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageMinimal debt reduces solvency pressure and limits interest-related cash demands while Eledon funds clinical development. This provides greater financial flexibility than a highly leveraged biotech, although the company still depends on its capital base and future financing to sustain operations.

Negative Factors

No Product RevenueWith no reported product revenue, Eledon currently lacks an operating sales base to fund research, clinical trials, or corporate expenses. Its financial progress remains dependent on development success and access to external capital until a product can be commercialized.

Eledon Pharmaceuticals (2TK) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 225.09M
Dividend Yield: ―
Average Volume (3M): 617
Price to Earnings (P/E): -2.8
Beta (1Y): 0.96
Revenue Growth: ―
EPS Growth: -1945.00%
Country: Germany
Employees: 33
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Eledon Pharmaceuticals Business Overview & Revenue Model

Company Description

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation...

Eledon Pharmaceuticals Risk Analysis

Eledon Pharmaceuticals disclosed 39 risk factors in its most recent earnings report. Eledon Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.Our financial condition raises substantial doubt as to our ability to continue as a going concern if we are unable to raise additional financing to fund our operations.Q2, 2026

Eledon Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:2TK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MGNX	47Neutral	$152.88M	-10.91	-31.27%	―	1.32%	59.94%
FATE	43Neutral	$249.23M	-1.98	-65.08%	―	-23.36%	27.52%
BCYC	42Neutral	$256.17M	-1.80	-26.02%	―	194.79%	43.93%
PRQR	42Neutral	$196.16M	-3.13	-68.44%	―	19.49%	-4.53%
SABS	39Underperform	$304.80M	0.94	-6.74%	―	-100.00%	95.16%

* Healthcare Sector Average

Performance Comparison

DE:2TK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:2TK	Eledon Pharmaceuticals, Inc.	2.60	-1.06	-28.96%
MGNX	MacroGenics Inc	2.40	0.82	51.90%
FATE	Fate Therapeutics Inc	2.08	0.82	65.08%
PRQR	ProQR Therapeutics BV	1.39	-1.20	-46.33%
BCYC	Bicycle Therapeutics	3.66	-3.60	-49.59%
SABS	Sab Biotherapeutics, Inc.	3.35	0.10	3.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Eledon Pharmaceuticals AI Stock Analysis